anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
For healthspan and lifespan, ERK, AMPK and mTORC1 represent critical pathways and inflammation is a centrally important hallmark1-7. Here we examined whether IL-11, a pro-inflammatory cytokine of the IL-6 family, has a negative effect on age-associated disease and lifespan. As mice age, IL-11 is upregulated across cell types and tissues to regulate an ERK-AMPK-mTORC1 axis to modulate cellular, tissue- and organismal-level ageing pathologies. Deletion of Il11 or Il11ra1 protects against metabolic decline, multi-morbidity and frailty in old age. Administration of anti-IL-11 to 75-week-old mice for 25 weeks improves metabolism and muscle function, and reduces ageing biomarkers and frailty across sexes. In lifespan studies, genetic deletion of Il11 extended the lives of mice of both sexes, by 24.9% on average. Treatment with anti-IL-11 from 75 weeks of age until death extends the median lifespan of male mice by 22.5% and of female mice by 25%. Together, these results demonstrate a role for the pro-inflammatory factor IL-11 in mammalian healthspan and lifespan. We suggest that anti-IL-11 therapy, which is currently in early-stage clinical trials for fibrotic lung disease, may provide a translational opportunity to determine the effects of IL-11 inhibition on ageing pathologies in older people.
Dysphagia is common in patients with acute stroke and deteriorates the overall outcome (1). Transesophageal echocardiography (TEE) is a routine examination in the diagnostic workup of stroke etiology. In cardiac surgery it is known as cause of postoperative dysphagia (2).

Using flexible endoscopic evaluation of swallowing (FEES) T.E.D.R.A.S., as a prospective, blinded, randomized and controlled study, includes patients in two groups in order to test the influence of TEE on swallowing in acute stroke: an intervention group and a control group. FEES is performed for analysis of swallowing in the intervention group (1) one day before TEE, (2) 2-4 hours after TEE, (3) 24 hours after TEE. In the control group FEES is performed on three consecutive days with TEE taking place any time after the last FEES. Validated scores assess dysphagia severity in both groups.
The hyperthermic treatment is applied to synthesis vascular smooth muscle cells that have undergone the growth stimulation, whereby only the abnormal growth is selectively inhibited without having an adverse effect on the surrounding normal cells. The timing of the hyperthermic treatment is preferably after the growth stimulation, more preferably 2 hours after the growth stimulation. The hyperthermic treatment temperature is preferably in the range of from 42° C. to 44° C., and 43° C. is optimal. The hyperthermic treatment time is preferably in the range of from 90 to 180 minutes, and 120 minutes is optimal. Outside the ranges of the hyperthermic treatment conditions, the growth inhibition effect might be insufficient, the normal contraction type smooth muscle cells might be brought to cell death, or the growth of the vascular endothelial cells might be inhibited. The hyperthermic treatment is a safe therapy with less pain to patients, which can be clinically applied as a method for hindering restenosis after coronary lesion angioplasty.
Twice-yearly community-wide treatment delivered by drug distributors door to door or via community gatherings, depending upon the format of the prior LF program, for three years. All individuals above the age of 12 months will receive a single dose of albendazole.
This will be a prospective, randomized and open clinical study. From a sample of patients hospitalized for myocardial revascularization surgery, followed at the cardiac surgery outpatient clinic, 20 research participants, male, aged over 40 years, non-diabetic or diabetic with disease duration of less than 10 years, glycated hemoglobin \<8% and non-user of NPH insulin, body mass index (BMI) between 20 and 34.9kg/m2 and glomerular filtration rate above 45mL/min who will be monitored at the Hospital de Clínicas/UNICAMP and randomized to receive pioglitazone hydrochloride 45mg/day for 5 days before surgery. The amount of S1P in HDL at baseline (before surgery) will be assessed. This same measurement will be repeated on day 5 (coinciding with the day of surgery) after using pioglitazone hydrochloride 45mg/day. In addition, on the day of surgery, a saphenous vein fragment of approximately 2 cm and an internal thoracic artery fragment of approximately 1 cm will be collected, which will not impair the quality of the graft nor the extent of the material to be used as a graft, because in this case the vascular material is abundant. An aortic artery button and an atrial appendage button will also be collected, which will be discarded. In addition, the results of serum troponin levels in the first 24h post-SVR (6, 12, 24h) will be evaluated to estimate the extent of troponin release. Postoperative examination.
OBJECTIVE: The glymphatic system serves as a perivascular pathway that aids in clearing liquid and solute waste from the brain, thereby enhancing neurological function. Disorders in glymphatic drainage contribute to the development of vasogenic edema following cerebral ischemia, although the molecular mechanisms involved remain poorly understood. This study aims to determine whether a deficiency in dystrophin 71 (DP71) leads to aquaporin-4 (AQP4) depolarization, contributing to glymphatic dysfunction in cerebral ischemia and resulting in brain edema.
METHODS: A mice model of middle cerebral artery occlusion and reperfusion was used. A fluorescence tracer was injected into the cortex and evaluated glymphatic clearance. To investigate the role of DP71 in maintaining AQP4 polarization, an adeno-associated virus with the astrocyte promoter was used to overexpress Dp71. The expression and distribution of DP71 and AQP4 were analyzed using immunoblotting, immunofluorescence, and co-immunoprecipitation techniques. The behavior ability of mice was evaluated by open field test. Open-access transcriptome sequencing data were used to analyze the functional changes of astrocytes after cerebral ischemia. MG132 was used to inhibit the ubiquitin-proteasome system. The ubiquitination of DP71 was detected by immunoblotting and co-immunoprecipitation.
RESULTS: During the vasogenic edema stage following cerebral ischemia, a decline in the efflux of interstitial fluid tracer was observed. DP71 and AQP4 were co-localized and interacted with each other in the perivascular astrocyte endfeet. After cerebral ischemia, there was a notable reduction in DP71 protein expression, accompanied by AQP4 depolarization and proliferation of reactive astrocytes. Increased DP71 expression restored glymphatic drainage and reduced brain edema. AQP4 depolarization, reactive astrocyte proliferation, and the behavior of mice were improved. After cerebral ischemia, DP71 was degraded by ubiquitination, and MG132 inhibited the decrease of DP71 protein level.
CONCLUSION: AQP4 depolarization after cerebral ischemia leads to glymphatic clearance disorder and aggravates cerebral edema. DP71 plays a pivotal role in regulating AQP4 polarization and consequently influences glymphatic function. Changes in DP71 expression are associated with the ubiquitin-proteasome system. This study offers a novel perspective on the pathogenesis of brain edema following cerebral ischemia.
PROBLEM TO BE SOLVED: To provide combination chemotherapy for AIDS treatment which is chemotherapeutic control with blood heating/supercooling, and genes, vaccine, narcotic, medicine, equipment, food, or others.SOLUTION: First, high-temperature heat treatment for adjusting collected blood from 38°C to about 50°C is performed. Next, low-temperature cooling treatment for adjusting the collected blood after the high-temperature heat treatment from 4°C to -20°C is performed. High-temperature heat treatment for adjusting the collected blood after the low-temperature cooling treatment to a human body temperature from 35.5°C to 36.5°C is performed. In a method of such a rise/fall of a temperature, the rise/fall of the temperature is performed by use of a high-speed cooling centrifugal separator. A method of a procedure is performed in a form like a bypass of a blood vessel. As the next process, gene treatment is performed by use of a syringe. Next, chemotherapy is performed.
NEW MATERIAL:A hepatic reparative factor, fractionated from a homogenate of an intestine mucous membrane of an animal and consisting of a hepatocyte growth control factors consisting of a complex of thermostable glycoprotein, having 6,000-50,000 molecular weight. USE:A cultivation promoter for hepatocytes or liver function promoter. PREPARATION:For example small intestines of cattle, pig, etc., is finely cut and washed with cold water to remove the contents. Only an intestinal epithelial mucous membrane part is then excoriated and ablated from the muscular and sheath membrane layers. A phosphoric acid buffer solution is subsequently added to homogenize the separated epithelial mucous membrane. The produced homogenate is ultracentrifuged to separate the supernatant liquid, which is then heat-treated at 100 deg.C for 3-5min., centrifuged and dialyzed against the phosphoric acid buffer solution. Furthermore, this dialyzate is concentrated and subjected to gel filtration to collect a fraction having 6,000-50,000 molecular weight. Thereby the aimed hepatic reparative factor is obtained.
Provided are a high-stability liposome, a preparation method therefor, and use thereof. A liposome composition comprises: 2-5 parts by weight of liquid grease, 3-10 parts by weight of solid grease, 5-30 parts by weight of phospholipid, 3-10 parts by weight of gelatin, 1-7 parts by weight of active ingredients, and 20-70 parts by weight of water. The liquid grease is one or more of caprylic/capric triglyceride, soybean oil, and sunflower seed oil. The solid grease is one or more of mono/diglycerol fatty acid ester, citrate, palm stearin, and beewax. The phospholipid is phospholipid with a phosphatidylcholine content of 30 wt%-60 wt%. The gelatin is gelatin with a Bloom value of 200-300. The liposome composition does not comprise an excipient or comprises 20-70 parts by weight of an excipient. The liposome herein does not comprise cholesterol, and has the characteristics of high temperature resistance and high stability.
OBJECTIVE: This study aims to determine the prevalence of vestibular schwannoma (VS) among patients presenting with sudden hearing loss (SHL) and to characterize the clinical features of individuals diagnosed with both VS and SHL.
METHODS: We conducted an observational retrospective review at a tertiary referral center, spanning a 30-year period, focusing on patients diagnosed with SHL where VS was confirmed as the underlying cause. We included patients meeting these criteria while excluding those lacking imaging or with a pre-existing diagnosis of VS. We evaluated the audiological characteristics at the time of diagnosis and assessed clinical outcomes following treatment.
RESULTS: Among the 403 patients presenting with SHL during the study period, 9 (2.2%) were diagnosed with VS, aged between 25 and 72 years. Although audiometric profiles varied, high-frequency hearing loss predominated, mostly categorized as mild to moderate. Six patients (66%) had Koos grade I-II schwannomas. Only 2 patients achieved complete hearing recovery post-treatment, while 4 showed no improvement.
CONCLUSIONS: VS is a rare etiology of SHL, accounting for slightly over 2% of cases. Its symptomatology, severity, and audiometric patterns do not significantly differ from SHL caused by other factors. Tumor size does not correlate with hearing characteristics. Treatment modalities resemble those for other SHL cases, and hearing improvement does not obviate the necessity for follow-up magnetic resonance imaging (MRI) scans.
Although some studies investigated the relationship of dam milk production (DMP) with offspring birth weight and productive performance, limited information is available on the association of level of DMP with reproductive performance in dairy cows. Therefore, the present study was conducted to understand whether dams with various levels of milk production produce offspring with different fertility. In study I, offspring were classified based on the level of DMP into five categories, including DMP1 (dams with <10.00 × 103 kg of 305-day milk production), DMP2 (dams with ≥10.00 × 103 kg and <12.00 × 103 kg of 305-day milk production), DMP3 (dams with ≥12.00 × 103 kg and <14.00 × 103 kg of 305-day milk production), DMP4 (dams with ≥14.00 × 103 kg and <16.00 × 103 kg of 305-day milk production) and DMP5 (dams with ≥16.00 × 103 kg of 305-day milk production). In study I, data of birth weight, milk yield and reproductive variables of 14,536 offspring born to lactating dams and corresponding data of DMP were retrieved. In study II, blood samples (n = 339) were collected from offspring in various categories of DMP for measurement of serum AMH. Offspring were heavier at birth in DMP4 and DMP5 categories than DMP1 and DMP2 categories (P < 0.05). Milk yield of offspring increased as DMP elevated (P < 0.05); however, offspring in DMP1 and DMP2 categories produced higher milk as compared with their dams during primiparity (P < 0.05) whereas offspring in DMP3, DMP4 and DMP5 categories produced less milk as compared with their dams during primiparity (P < 0.05). Milk fat to protein ratio during the first month of lactation was greater in DMP4 and DMP5 categories than DMP1 category (P < 0.05). Offspring of DMP4 and DMP5 categories were inseminated and conceived at younger ages than offspring of DMP1 category during nulliparity (P < 0.05). Calving to conception interval was longer in DMP5 than DMP1 category in primiparous offspring (P < 0.05), but concentration of AMH did not differ among various categories of DMP (P > 0.05). In conclusion, dams with greater level of milk production produced heavier offspring with higher milk yield but worse transgenerational improvement in milk production and diminished reproductive performance, which were seemingly under higher pressure of negative energy balance during the first month of lactation.
The present invention relates to the field of therapeutic immunization, specifically with the use of a novel hepatitis B virus (HBV) antigen formulation for cell stimulation. The formulation is formed by HBV surface antigen (HBsAg) and nucleocapsid antigen (HBcAg) precipitates in suspension. The formulation contains said antigens as precipitates in suspension as particles with sizes less than 500 nm and greater than 500 nm, in a mixture in which the proportion between the particles of the sizes mentioned is between 50% - 50% and 80% - 20%, respectively. The selection of a range of particle sizes allows the levels of stimulation of various cell types to be maximized. In addition, a description is given of a method for cell stimulation using said formulation and the subsequent passive immunization of patients with chronic hepatitis B, based on the maximum in vivo or in vitro stimulation of heterologous or autologous cells (dendritic cells, B cells and macrophages). The cells stimulated with this formulation are transferred to patients with a chronic HBV infection.
PROBLEM TO BE SOLVED: To provide a new ultraviolet-absorbing compound soluble in fat, having strong ultraviolet-absorbing property and useful as a component for cosmetic, etc. SOLUTION: The objective compound is 3-acetamido-4-hydroxybenzoic acid butyl ester expressed by formula. The compound of formula can be produced by culturing a microorganism belonging to the genus Pelagiobacter and capable of producing the compound of formula (e.g. Pelagiobacter sp.F-104) in a medium to effect the production and accumulation of the compound of formula and collecting the compound from the cultured product. A medium containing a carbon source (e.g. glucose), a nitrogen source (e.g. ammonium chloride) and inorganic material (e.g. common salt and potassium chloride), etc., is used as the culture medium. The culture is preferably carried out by liquid culture preferably at 30-35 deg.C and pH 7-8. The compound of formula is produced and accumulated by the culture for 3-5 days.  The cultured product is separated into the filtrate and bacterial cell by filtration and centrifugal separation and the cell is extracted with aqueous methanol, aqueous ethanol, etc.
OBJECTIVES: To investigate the structural characteristics of intestinal flora in children with sepsis and its association with inflammatory response.
METHODS: A prospective cohort study was conducted. The children with sepsis who were admitted from December 2021 to January 2023 were enrolled as the sepsis group, and the children with non-sepsis who were admitted during the same period were enrolled as the non-sepsis group. The two groups were compared in terms of the distribution characteristics of intestinal flora, peripheral white blood cell count (WBC), C reactive protein (CRP), and cytokines, and the correlation of the relative abundance of fecal flora with WBC, CRP, and cytokines was analyzed.
RESULTS: At the genus level, compared with the non-sepsis group, the sepsis group had significantly lower relative abundance of Akkermansia, Ruminococcus, and Alistipes and significantly higher relative abundance of Enterococcus, Streptococcus, and Staphylococcus (P<0.05). At the phylum level, Proteobacteria was the dominant phylum (37.46%) in the group of children with a score of ≤70 from the Pediatric Critical Illness Score (PICS), and Firmicutes was the dominant phylum in the group of children with a score of 71-80 or 81-90 from the PICS (72.20% and 43.88%, respectively). At the genus level, among the 18 specimens, 5 had a relative abundance of >50% for a single flora. Compared with the non-sepsis group, the sepsis group had significant higher levels of WBC, CRP, interleukin-6 (IL-6), interleukin-10 (IL-10), and tumor necrosis factor-α (P<0.05). The Spearman's rank correlation analysis showed that at the genus level, the relative abundance of Ruminococcus, Alistipes, and Parasutterella in the sepsis group was negatively correlated with the levels of WBC, CRP, and IL-6 (P<0.05); the relative abundance of Enterococcus was positively correlated with the CRP level (P<0.01); the relative abundance of Streptococcus and Staphylococcus was positively correlated with the levels of CRP and IL-6 (P<0.05); the relative abundance of Streptococcus was positively correlated with WBC (P<0.05).
CONCLUSIONS: Intestinal flora disturbance is observed in children with sepsis, and its characteristics vary with the severity of the disease. The structural changes of intestinal flora are correlated with inflammatory response in children with sepsis.
An electroencephalogram (EEG)-basis method and system is designed to assess the adverse effect of impulse control disorders in patients with Parkinson's disease. The method and system are based on a preparation step, an acquisition step, and an analysis step. The preparation step is to set up an evaluation system in order to cap an EEG acquisition headset on a test subject and initiate a brief cognitive test battery. The acquisition step is to utilize the evaluation system to measure two sets of EEG signals called reference and inference signals before and after taking drugs, respectively. The analysis step is to characterize the distinction between the measured reference and inference EEG signals by obtaining at least one differential feature corresponding to the engaged impulse-control test. This step is used to objectively assess the test subject’s impulse control integrity. The present method and system can be employed to longitudinally monitor the risk of impulse control disorders during ongoing treatment and thereby provide the EEG-basis evidence for the test patient in order to continue or adjust the personalized drug treatment.
INTRODUCTION: Alport syndrome (AS) is one of the most common fatal hereditary renal diseases in human, with a high risk of progressing to end-stage renal disease without effective treatments. Mesenchymal stem cells (MSCs) have recently emerged as a promising therapeutic strategy for chronic kidney disease. However, the safety and therapeutic potential of MSC transfusion for patients with AS are still need to be confirmed. Therefore, we have designed a clinical trial to evaluate the hypothesis that intravenous infusion of human umbilical cord-derived MSC (hUC-MSC) is safe, feasible, and well-tolerated in children with AS.
METHODS AND ANALYSIS: We report the protocol of the first prospective, open-label, single-arm clinical trial to evaluate the safety and preliminary efficacy of hUC-MSC transfusion in children with early-stage AS. Paediatric patients diagnosed with AS who have persistent albuminuria will be candidates for screening. Twelve eligible patients are planned to recruit and will receive hUC-MSC infusions under close safety monitoring, and complete the efficacy assessments at scheduled follow-up visits. The primary endpoints include the occurrence of adverse events to assess safety and the albuminuria level for efficacy evaluation. Secondary endpoint assessments are based on haematuria and glomerular filtration measurements. Each patient's efficacy endpoints will be evaluated against their baseline levels. Additionally, the underlying mechanism of hUC-MSC therapy will be explored through transcriptomic and proteomic analysis of blood and urine samples.
ETHICS AND DISSEMINATION: The protocol (V.1.0, date 17 January 2015) was approved by the institutional review board of the Affiliated Taihe Hospital of Hubei University of Medicine (ethical approval 03 March 2015). Written informed consent will be obtained from the patient and/or guardians before study specific process. In addition to publication in a peer-reviewed scientific journal, a lay summary of study will be available for participants and the public on the Chinese Organization for Rare Disorders website (http://www.cord.org.cn/).
TRIAL REGISTRATION NUMBER: ISRCTN62094626.
FIELD: food industry and technology. SUBSTANCE: invention relates to method for preparing improved pressed product. Method involves agglomeration of their components. Invention relates also to the pressed product and agglomerate prepared by indicated method. Isomaltulose, isomalt and/or 1.6-GPS- and 1,1-GPM-containing mixture is ground in dry form ground fraction of isomaltulose, isomalt or 1,6-GPS- and 1,1-GPM-containing fraction with particles diameter 100 mcm are prepared or separated simultaneously or after grinding process. Ground fraction with addition of liquid binding agent is agglomerated and pressed to obtain the pressed product. Invention provides preparing product of high strength under low value of pressure pressing. EFFECT: improved preparing method. 17 cl, 3 dwg, 2 ex
QUVIVIQ is a central nervous system (CNS) depressant that can impair daytime wakefulness even when used as prescribed. CNS-depressant effects may persist in some patients for up to several days after discontinuing QUVIVIQ. Prescribers should advise patients about the potential for next-day somnolence.

Driving ability was impaired in some subjects taking QUVIVIQ 50 mg [see Clinical Studies (14.2)]. The risk of daytime impairment is increased if QUVIVIQ is taken with less than a full night of sleep remaining or if a higher than recommended dose is taken [see Dosage and Administration (2.1)]. If QUVIVIQ is taken in these circumstances, caution patients against driving and other activities requiring complete mental alertness.

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. Dosage adjustments of QUVIVIQ and of concomitant CNS depressants may be necessary when administered together because of potentially additive effects. The use of QUVIVIQ with other drugs to treat insomnia is not recommended. Advise patients not to consume alcohol in combination with QUVIVIQ because co-administration of QUVIVIQ with alcohol resulted in additive effects on psychomotor performance [see Drug Interactions (7.1)].

Because QUVIVIQ can cause drowsiness, patients, particularly the elderly, are at a higher risk of falls.